Cargando…
Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations
The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other...
Autores principales: | Rodriguez-Porcel, Federico, Wyman-Chick, Kathryn A., Abdelnour Ruiz, Carla, Toledo, Jon B., Ferreira, Daniel, Urwyler, Prabitha, Weil, Rimona S., Kane, Joseph, Pilotto, Andrea, Rongve, Arvid, Boeve, Bradley, Taylor, John-Paul, McKeith, Ian, Aarsland, Dag, Lewis, Simon J. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059356/ https://www.ncbi.nlm.nih.gov/pubmed/35491418 http://dx.doi.org/10.1186/s40035-022-00299-w |
Ejemplares similares
-
Correction: Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations
por: Rodriguez-Porcel, Federico, et al.
Publicado: (2022) -
Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort
por: Berge, Guro, et al.
Publicado: (2014) -
Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies
por: Breitve, Monica H., et al.
Publicado: (2018) -
A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer’s disease
por: Breitve, Monica H, et al.
Publicado: (2014) -
A Longitudinal Study of Neurocognition in Dementia with Lewy Bodies Compared to Alzheimer’s Disease
por: Breitve, Monica H., et al.
Publicado: (2018)